Table 2.

Anti-Proliferative Activity of Diheteroarylnona-1,3,6,8-tetraen-5-ones

Compd.	IC50 (μM)a			IC50 (curcumin)/IC50(dienone)
	PC-3b	DU145c	LNCaPd	PC-3b	DU145c	LNCaPd
Curcumin	25.43 ± 2.15	26.23 ± 0.65	13.61 ± 2.69	1	1	1
59	6.21 ± 0.15	6.38 ± 0.65	6.85 ± 0.35	4	4	2
60	3.00 ± 1.18	7.37 ± 1.44	8.01 ± 2.87	9	4	2
61	10.47 ± 2.43	5.30 ± 2.36	8.09 ± 1.20	2	5	2
62	4.19 ± 0.24	4.19 ± 1.35	2.58 ± 1.04	6	6	5
63	24.77 ± 8.06	11.35 ± 2.96	>20	1	2	<1
64	>20	18.53 ± 10.59	>20	<1	1	<1
65	3.86 ± 0.23	2.45 ± 1.29	6.14 ± 2.68	7	11	5
66	7.43 ± 4.05	2.69 ± 0.99	4.94 ± 0.47	3	10	5
67	>15	>15	> 20	<1.7	<1.7	<1
68	2.36 ± 0.56	1.21 ± 0.43	2.43 ± 1.31	11	22	6
69	2.50 ± 1.06	1.75 ± 0.52	5.62 ± 3.57	10	15	2
70	45.69 ± 19.56	3.59 ± 2.63	17.53 ± 4.89	<1	7	<1
71	10.39 ± 4.71	8.29 ± 2.97	6.05 ± 4.93	3	3	2
72	5.22 ± 3.97	6.55 ± 3.26	4.94 ± 0.47	5	4	3
73	>15	>15	5.89 ± 2.64	<1.7	<1.7	2.3
74	1.79 ± 0.24	1.60 ± 0.08	1.63 ± 0.34	14	16	8
75	1.14 ± 0.12	1.78 ± 0.13	2.17 ± 0.2	22	15	6
76	11.74 ± 0.61	14.36 ± 0.34	13.62 ± 3.64	2	2	1
77	>15	>15	17.71 ± 4.88	<1.7	<1.7	<1
78	1.09 ± 0.17	1.20 ± 0.01	0.98 ± 0.19	23	22	14
79	2.63 ± 0.51	3.50 ± 0.17	0.97 ± 0.34	10	8	14
80	2.48 ± 0.41	2.70 ± 0.28	1.49 ± 2.24	10	10	9
81	7.24 ± 0.58	9.76 ± 0.66	3.65 ± 0.85	4	3	3.7
82	2.67 ± 0.26	3.36 ± 0.36	3.00 ± 0.77	10	8	4.5
83	2.82± 0.38	4.08 ± 0.36	4.31 ± 0.99	9	6	3.2

^aIC₅₀ is the drug concentration effective in inhibiting 50% of the cell viability measured by WST-1 cell proliferation assay (WST-1) or trypan blue exclusion assay (TB) after 3 days exposure.

^bHuman androgen-insensitive prostate cancer cell line

^cHuman androgen-insensitive prostate cancer cell line

^dHuman androgen-sensitive prostate cancer cell line